Not checked for notices yet.

Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class

Micah Rapp, Yicheng Guo, Eswar R. Reddem and 14 more

Cell Reports · 2021

doi:10.1016/j.celrep.2021.108950

References 90

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
Overview of the CCP 4 suite and current developments · 2011
No notice
16.
Features and development of Coot · 2010
No notice
17.
The PDB_REDO server for macromolecular structure model optimization · 2014
No notice
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
Integration, scaling, space-group assignment and post-refinement · 2010
No notice
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
Towards automated crystallographic structure refinement with phenix.refine · 2012
No notice
27.
MolProbity : all-atom structure validation for macromolecular crystallography · 2009
No notice
28.
Phaser crystallographic software · 2007
No notice
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
PHENIX : a comprehensive Python-based system for macromolecular structure solution · 2010
No notice
31.
ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimation · 2016
Corrected
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
ISOLDE : a physically realistic environment for model building into low-resolution electron-density maps · 2018
No notice
39.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
41.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
42.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
43.
A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020
No notice
44.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
45.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
46.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
47.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
48.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
49.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
50.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
51.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
52.
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 · 2020
No notice
53.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
54.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
55.
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail · 2020
No notice
56.
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020
No notice
57.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
58.
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model · 2020
No notice
59.
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike · 2020
Corrected
60.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
61.
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies · 2020
No notice
62.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
63.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
64.
Structural basis of a shared antibody response to SARS-CoV-2 · 2020
No notice
65.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
66.
Distinct conformational states of SARS-CoV-2 spike protein · 2020
No notice
67.
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody · 2020
No notice
68.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
69.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
70.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
71.
Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation · 2020
No notice
72.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
73.
Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein · 2020
No notice
74.
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model · 2020
No notice
75.
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms · 2020
No notice
76.
An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain · 2020
No notice
77.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
78.
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate · 2020
No notice
79.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
80.
Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation · 2020
No notice
81.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
82.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
83.
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity · 2020
No notice
84.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
85.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
86.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
87.
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England · 2021
No notice
88.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
89.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
90.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 4

Mucosal immune response in biology, disease prevention and treatment · 2025
No notice
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
No notice
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion · 2021
No notice
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.